Adapt Pharma Announces Fast Track Designation From FDA for Naloxone Nasal Spray

February 17, 2015

Adapt Pharma Announces Fast Track Designation From FDA for Naloxone Nasal Spray

Dublin, Ireland—February 17, 2015—Adapt Pharma Limited (“Adapt Pharma”) today announced that its development program fornaloxone nasal spray, a drug designed to treat opioid overdose, has received Fast Track designation by the United States Food and Drug Administration (“FDA”).

The Fast Track program of the FDA is designed to facilitate the development, and expedite the review, of drugs to treat serious conditions and fulfill unmet medical needs. The purpose is to get important new drugs to the patient earlier.

About Adapt Pharma Limited

Adapt Pharma Limited is a privately held pharmaceutical company committed to making a positive impact on the lives of patients with specialty medical conditions. Adapt Pharma’s strategy is to identify, evaluate, selectively acquire, and enhance the value of late-stage development—and FDA approved—pharmaceutical products. Adapt Pharma’s company headquarters is in Dublin, Ireland.

Media Contact

media@adaptpharma.com